PRIVILEGED AND CONFIDENTIAL ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP 555 South Hope Street, Suite 4400 Los Angeles, California 90071 Telephone: (213) 486-7200 Facsimile: (213) 486-7201
MEMORANDUM
TO: James Prentice, Sandra Tung, Tiffany Rosenthal, Andrew Fitzpatrick — Calderwood & Harkness LLP
FROM: Leonard Cross, Partner, Tax — Calderwood & Harkness LLP
DATE: August 18, 2023
RE: Preliminary Purchase Price Allocation Under IRC § 1060 — Sale of OncuPath™ Companion Diagnostics Business by Genome Dx Therapeutics Inc. to Meridian Precision Diagnostics, Inc.
MATTER NO.: 1013-00006&A-4471
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to set forth the preliminary purchase price allocation ("PPA") for the $140,000,000 asset purchase of the OncuPath™ companion diagnostics business line (the "OncuPath Business") by Meridian Precision Diagnostics, Inc. ("Buyer" or "Meridian") from Genome Dx Therapeutics Inc. ("Seller" or "GDT"), pursuant to Section 2.6 of the Asset Purchase Agreement dated May 11, 2023 (the "APA"). The transaction closed on August 8, 2023 (the "Closing Date").
The allocation is governed by Internal Revenue Code ("IRC") § 1060 and Treasury Regulations § 1.1060-1, which require both Buyer and Seller to allocate the purchase price among the acquired assets using the residual method prescribed by IRC § 338(b)(5) and the seven asset classes set forth in Treasury Regulations § 1.338-6. The residual method mandates that the aggregate consideration be allocated first to the asset classes with the most readily determinable fair market values (Classes I through VI), with any remainder allocated to Class VII (goodwill and going-concern value).
Pursuant to APA Section 2.6, the parties must agree upon a final allocation within 120 days following the Closing Date — that is, by December 6, 2023. Both Seller and Buyer are contractually obligated to file consistent IRS Form 8594 (Asset Acquisition Statement Under Section 1060) with their respective federal income tax returns for the taxable year in which the Closing occurred. Neither party may take a position on any tax return, refund claim, or in any tax proceeding that is inconsistent with the agreed allocation absent a "determination" (as defined in IRC § 1313(a)) to the contrary.
This memorandum presents the preliminary allocation prepared in coordination with Haverford & Lane LLP (Douglas Crane, Engagement Partner), GDT's carve-out auditors and tax advisors, based on currently available fair market value estimates. The allocation remains subject to negotiation with Meridian and its counsel, Whitfield Sayer & Gregg LLP (Jonathan Whitfield, lead partner; Rachel Dempsey, associate), as well as refinement following the finalization of the working capital true-up and independent appraisals.
The total consideration subject to allocation is $140,000,000, comprising a $126,000,000 closing cash payment and up to $14,000,000 in earnout consideration payable upon the achievement of two defined clinical milestones within thirty-six months following the Closing Date. The preliminary allocation presented herein distributes this consideration across the seven asset classes prescribed by Treasury Regulations § 1.338-6, with particular attention to the character of gain implications for Seller and the depreciation and amortization benefits available to Buyer. As discussed in greater detail below, the allocation reflects a tension between Seller's preference for maximizing the residual allocated to goodwill (Class VII), which generates long-term capital gain, and Buyer's preference for maximizing the amounts allocated to depreciable and amortizable assets (Classes IV through VI), which accelerate cost recovery.
The sections that follow provide a detailed overview of the transaction, the applicable legal framework, the treatment of earnout consideration, the preliminary allocation by asset class, the tax implications for both Seller and Buyer, and the recommended next steps for finalizing the allocation in advance of the contractual deadline.
II. Transaction Overview
A. Parties
Seller. Genome Dx Therapeutics Inc. ("GDT") is a Delaware corporation headquartered at 10250 Science Center Drive, Suite 600, San Diego, California 92121. GDT's Employer Identification Number is 47-3892061. GDT is a privately held C corporation engaged in the development, manufacturing, and commercialization of molecular diagnostic products, including the OncuPath companion diagnostics business line and the GenoStrat™ liquid biopsy platform. GDT was incorporated in the State of Delaware in 2014 and has conducted all of its operations from facilities located in San Diego and Carlsbad, California.
Buyer. Meridian Precision Diagnostics, Inc. ("Meridian") is a Delaware corporation headquartered at 2400 Meridian Parkway, Suite 300, Durham, North Carolina 27713. Meridian's Employer Identification Number is 56-4210783. Meridian is a growth-stage precision diagnostics company focused on oncology and immunology companion diagnostics, with established operations in the southeastern United States and a growing commercial footprint across academic medical centers and integrated delivery networks nationwide.
Seller's Equity Sponsor. Pinnacle Biosciences Partners Fund III, L.P. ("Pinnacle" or the "Fund"), a Delaware limited partnership (EIN 83-1726450), holds approximately 68.4% of GDT's outstanding common stock. The general partner of the Fund is Pinnacle Biosciences Partners GP III, LLC, and the managing partners are Nathaniel Hargrove and Priya Ramanathan. Pinnacle initially invested in GDT through the Fund's Series B financing round in 2017 and led subsequent financing rounds in 2019 and 2021. As the majority equity holder, Pinnacle participated actively in the negotiation of the APA and the structuring of the transaction, including the purchase price allocation framework set forth in APA Section 2.6. The gain recognized by GDT at the corporate level will ultimately be distributed to Pinnacle and GDT's other shareholders, and the character of that gain — particularly the split between ordinary income and long-term capital gain — has significant implications for Pinnacle's limited partners and for the Fund's overall returns.
B. Structure and Consideration
The transaction is structured as an asset purchase — not a stock deal. Meridian acquired substantially all of the assets exclusively related to GDT's OncuPath companion diagnostics assay line (the "OncuPath Business") pursuant to the APA. The asset purchase structure was elected for a combination of tax and business reasons, including Meridian's desire to obtain a full step-up in the tax basis of all acquired assets and to avoid the assumption of unknown or contingent liabilities associated with a stock acquisition.
The total consideration for the Purchased Assets is $140,000,000, structured as follows:
Closing Cash Payment. At the Closing on August 8, 2023, Meridian paid $126,000,000 in immediately available funds by wire transfer to GDT (less certain adjustments for the estimated working capital amount and closing prorations as provided in APA Section 2.3).
Earnout Consideration. In addition to the closing cash payment, Meridian agreed to pay up to $14,000,000 (representing 10% of the total consideration) in earnout payments upon the achievement of two specified clinical milestones within the thirty-six-month period following the Closing Date (the "Earnout Period"):
Milestone 1: $8,000,000 — payable upon FDA clearance or approval of the OncuPath-HER3™ assay as a companion diagnostic by August 8, 2025 (twenty-four months post-closing).
Milestone 2: $6,000,000 — payable upon the Centers for Medicare & Medicaid Services ("CMS") issuance of a unique HCPCS code for OncuPath-HER3™ and receipt of the first Medicare reimbursement payment thereunder by August 8, 2026 (thirty-six months post-closing).
The earnout milestones are binary in nature — each milestone is either achieved in full or not at all — and there are no partial payments or graduated thresholds. The aggregate maximum earnout payable is $14,000,000, and there is no minimum guaranteed earnout payment.
Escrow. At the Closing, $14,000,000 was deposited into a segregated escrow account at Ashgrove Equity Partners Escrow Services, Inc. (Account No. 8841-7023-5500) to secure GDT's indemnification obligations under Article IX of the APA. The escrow deposit does not reduce the total consideration for purposes of the purchase price allocation; it represents funds already included in the $126,000,000 closing cash payment that are being held by the escrow agent pending the expiration of the indemnification survival periods or the resolution of any indemnification claims.
Working Capital Adjustment. The APA provides for a post-closing working capital adjustment based on a target net working capital ("NWC") of $6,800,000, with a ± $350,000 collar (the "Collar"). If the final closing NWC, as determined from the closing balance sheet to be prepared by Haverford & Lane LLP (Douglas Crane, Engagement Partner), exceeds the target NWC by more than $350,000, Meridian will pay the excess to GDT; if the final closing NWC falls below the target NWC by more than $350,000, GDT will refund the shortfall to Meridian. The working capital true-up must be completed within ninety days following the Closing Date — that is, by November 6, 2023. Any NWC adjustment will modify the total consideration allocable under IRC § 1060 and will require a corresponding adjustment to the purchase price allocation, as discussed in Section IX below.
C. Purchased Assets
The Purchased Assets encompass all assets, intellectual property, contracts, inventory, equipment, regulatory filings, and goodwill exclusively related to the OncuPath Business, as described in APA Section 1.1 and Schedule 1.1(a). The principal categories of Purchased Assets are as follows:
intellectual Property. Fourteen (14) issued United States patents and seven (7) pending United States patent applications covering OncuPath assay technology, including probe design, signal amplification methods, and bioinformatics algorithms. In addition, the Purchased Assets include all trade secrets, proprietary know-how, and technical data related to the development, manufacture, and commercialization of OncuPath diagnostic assays.
Trademarks. Three registered trademarks in the OncuPath brand family: OncuPath™ (USPTO Reg. No. 5,847,321), OncuPath-HER3™ (USPTO Reg. No. 6,412,088), and OncuPath-GENOMARK™ (USPTO Reg. No. 6,118,754).
Licensed Technology. An exclusive license from Vantage Molecular Sciences, Inc. for probe-labeling technology pursuant to a license agreement dated September 12, 2019 (the "Vantage License"). Consent to the assignment of the Vantage License to Meridian was obtained from Vantage Molecular Sciences, Inc. on July 14, 2023, in accordance with APA Section 5.4.
Regulatory Assets. Three FDA-cleared 510(k) diagnostic assays: K201847, K193215, and K210562. In addition, a pending Premarket Approval ("PMA") supplement for the OncuPath-HER3™ assay (P230014), which was submitted to the FDA on January 30, 2023 and remains under review. The CLIA certificate of accreditation (ID: 05D2178493) for the OncuPath reference laboratory located at 4820 Towne Centre Drive, Suite 200, San Diego, California 92121 is also included among the Purchased Assets.
Real Property Interests. Leasehold interests in two facilities: (i) the laboratory and research and development facility at 4820 Towne Centre Drive, Suite 200, San Diego, California 92121, assigned to Meridian with the consent of Towne Centre Properties LLC (landlord consent dated July 28, 2023); and (ii) the manufacturing and kitting sublease at 925 Industrial Court, Carlsbad, California 92010 (sublease expiring December 31, 2025).
Customer Contracts and Commercial Relationships. All customer contracts, supplier agreements, and related commercial relationships exclusively pertaining to the OncuPath Business, including contracts with hospitals, reference laboratories, and pharmaceutical company partners, transferred pursuant to the Assignment and Assumption Agreement executed concurrently with the APA.
Equipment and Inventory. All laboratory instruments, diagnostic analyzers, sample processing equipment, manufacturing and kitting equipment, reagent inventory, consumable supplies, and finished goods inventory of OncuPath assay kits located at the San Diego and Carlsbad facilities.
Goodwill and Going-Concern Value. The goodwill, going-concern value, and assembled workforce value associated with the OncuPath Business.
D. Excluded Assets
The following categories of assets are expressly excluded from the Purchased Assets under APA Section 1.1(b) and are retained by GDT:
(i) The GenoStrat™ liquid biopsy platform and all other retained GDT business lines and associated assets, intellectual property, and contracts;
(ii) All corporate-level cash and cash equivalents of GDT;
(iii) Tax refunds and tax attributes attributable to pre-closing periods;
(iv) The GDT corporate name, logos, and all trademarks outside the OncuPath brand family;
(v) GDT's corporate books and records (other than the Transferred Books and Records as defined in the APA);
(vi) Employee benefit plan assets and related corporate-level insurance policies; and
(vii) Any rights of GDT under the APA itself or any ancillary agreement to the extent such rights relate to GDT's retained businesses.
The exclusion of the GenoStrat™ platform and other retained businesses is a critical structural feature of this transaction, as it ensures that the OncuPath Business is carved out as a standalone going concern while GDT continues to operate its remaining businesses independently.
III. Legal Framework — IRC § 1060 and the Residual Method
A. Statutory and Regulatory Framework
IRC § 1060(a) provides that in the case of any "applicable asset acquisition," the transferee's basis in the acquired assets — and the gain or loss of the transferor — shall be determined by allocating the consideration paid among the acquired assets in the same manner as amounts are allocated under IRC § 338(b)(5). This allocation methodology is commonly referred to as the "residual method."
An "applicable asset acquisition" is defined under IRC § 1060(c) as any transfer (whether direct or indirect) of assets constituting a trade or business, where the transferee's basis in such assets is determined wholly by reference to the consideration paid for such assets. Treasury Regulations § 1.1060-1(a)(1) amplifies this definition, providing that a group of assets constitutes a trade or business if their character is such that goodwill or going-concern value could under any circumstances attach to the assets, or if the use of the assets constitutes an active trade or business under IRC § 355.
The transaction that is the subject of this memorandum clearly constitutes an applicable asset acquisition within the meaning of IRC § 1060. Meridian acquired a comprehensive group of assets — including intellectual property, customer relationships, regulatory clearances, equipment, inventory, leasehold interests, and goodwill — that together constitute the OncuPath companion diagnostics business, an active, ongoing, revenue-generating trade or business. Meridian's tax basis in the Purchased Assets is determined entirely by reference to the $140,000,000 of consideration paid by Meridian pursuant to the APA. Accordingly, IRC § 1060 applies and requires both Buyer and Seller to allocate the aggregate consideration among the Purchased Assets using the residual method.
The residual method, as prescribed by IRC § 338(b)(5) and elaborated in Treasury Regulations § 1.338-6 and § 1.338-7, requires the aggregate consideration to be allocated among seven classes of assets, in a specified order of priority. The consideration is allocated first to the class of assets with the most readily determinable fair market value (Class I — cash and cash equivalents), and then sequentially through Classes II through VI based on the fair market values of the assets in each class. Any remaining unallocated consideration is then assigned to Class VII, which consists of goodwill and going-concern value. If the aggregate consideration is insufficient to fully allocate to the fair market values of assets in a particular class, the consideration is allocated ratably among the assets in that class in proportion to their relative fair market values, and no amount is allocated to any subsequent class.
The seven asset classes, together with a description of the types of assets included in each class, are set forth in Section III.B below.
B. The Seven Asset Classes (Treas. Reg. § 1.338-6)
Treasury Regulations § 1.338-6 establishes the following seven asset classes for purposes of applying the residual method:
Class I — Cash and Cash Equivalents. This class includes cash, demand deposits, and similar cash-equivalent items. Class I assets are not applicable in this transaction because the Purchased Assets expressly exclude all corporate-level cash and cash equivalents of GDT.
Class II — Actively Traded Personal Property, Certificates of Deposit, and Foreign Currency. This class includes actively traded personal property (within the meaning of IRC § 1092(d)(1)), certificates of deposit, and foreign currency. Class II assets are not applicable in this transaction, as no assets of this type are included among the Purchased Assets.
Class III — Accounts Receivable, Mortgages, Credit Card Receivables, and Similar Debt Instruments. This class includes accounts receivable, mortgages, and credit card receivables (other than those included in Class II). In this transaction, the OncuPath Business trade receivables are addressed through the post-closing working capital adjustment mechanism rather than as separately identified Purchased Assets. Any amounts ultimately treated as part of the NWC true-up will be reflected in adjustments to the aggregate consideration and allocated accordingly. For purposes of this preliminary allocation, no amount is separately allocated to Class III.
Class IV — Stock in Trade (Inventory) and Tangible Depreciable Personal Property. This class includes inventory (including raw materials, work-in-progress, and finished goods) and tangible personal property that is depreciable under IRC § 167. In this transaction, Class IV includes laboratory instruments, diagnostic analyzers, sample processing equipment, manufacturing and kitting equipment, reagent inventory, consumable supplies, and finished goods inventory of OncuPath assay kits.
Class V — All Assets Not in Classes I Through IV or Class VII. This class is a broad residual category that includes all assets not falling into any other class, including intangible assets such as patents, patent applications, trade secrets, covenants not to compete, customer relationships and contracts, licenses (including the Vantage License), FDA regulatory clearances, CLIA accreditation, and leasehold interests. Class V is the largest asset class in this transaction by dollar value.
Class VI — IRC § 197 Intangibles Other Than Goodwill and Going-Concern Value. This class includes section 197 intangibles (as defined in IRC § 197(d)) other than goodwill and going-concern value. In practice, the most common Class VI assets are trademarks and trade names. In this transaction, Class VI includes the three registered OncuPath trademarks: OncuPath™, OncuPath-HER3™, and OncuPath-GENOMARK™.
Class VII — Goodwill and Going-Concern Value. This class is the final residual class and includes goodwill, going-concern value, and any other intangible value not separately identifiable or allocable to Classes I through VI. Under the residual method, the amount allocated to Class VII is determined by subtracting the aggregate fair market values allocated to all other classes from the total consideration. In this transaction, the residual amount allocated to goodwill is $28,600,000.
C. Consistency Requirements
The consistency requirements applicable to the purchase price allocation operate at two levels: contractual and statutory.
At the contractual level, APA Section 2.6 provides that the parties shall agree upon a final allocation of the purchase price within 120 days following the Closing Date (by December 6, 2023), and that once agreed, the allocation shall be binding on both parties. Neither GDT nor Meridian may take a position on any federal, state, local, or foreign tax return, refund claim, or in any tax audit, examination, or other proceeding that is inconsistent with the agreed allocation, unless required to do so by a "determination" within the meaning of IRC § 1313(a) (i.e., a final court decision, closing agreement, or other final disposition).
At the statutory level, IRC § 1060(a) requires both Buyer and Seller to use the same allocation methodology — the residual method — and to report the allocation on IRS Form 8594 (Asset Acquisition Statement Under Section 1060) filed with their respective federal income tax returns for the taxable year that includes the Closing Date. Treasury Regulations § 1.1060-1(e) provides that if the parties enter into a written agreement allocating the consideration, such agreement is binding on both parties unless either can demonstrate that the agreed allocation was not arrived at through arm's-length negotiation. In this transaction, the negotiation between GDT (represented by Calderwood & Harkness LLP) and Meridian (represented by Whitfield Sayer & Gregg LLP) is clearly an arm's-length process between unrelated parties, and there is no basis to argue that the resulting allocation should not be respected for tax purposes.
Both GDT and Meridian are required to file IRS Form 8594 with their respective tax returns for the taxable year 2023 (or the taxable year that includes the August 8, 2023 Closing Date). If the aggregate consideration is subsequently adjusted — for example, as a result of the NWC true-up or the payment or non-payment of earnout milestones — a supplemental Form 8594 must be filed reflecting the revised allocation.
IV. Treatment of Earnout Consideration
A. Inclusion in Allocable Consideration
The total consideration for purposes of the purchase price allocation is $140,000,000, comprising the $126,000,000 closing cash payment and the $14,000,000 maximum earnout. A threshold question in structuring the allocation is whether the $14,000,000 earnout should be included in the aggregate consideration at the time of closing (i.e., treated as if the full amount were received at closing) or whether it should be deferred and allocated only as and when the milestone payments are actually made.
Under Treasury Regulations § 1.1060-1(c)(2), the allocation of consideration in an applicable asset acquisition must take into account contingent amounts to the extent provided under general tax principles. The regulations do not prescribe a single methodology for treating contingent consideration; rather, they incorporate by reference the broader "open transaction" versus "closed transaction" framework that applies to sales of property for contingent consideration.
Under the "closed transaction" approach, the aggregate consideration is treated as a fixed amount at the time of closing, with the contingent payments included at their fair market value or, if the contingent payments have a determinable maximum amount, at that maximum amount. If the earnout payments are ultimately less than the amount initially included, an adjustment to the allocation (and to the Seller's recognized gain) is made in the year in which the contingency is resolved.
Under the "open transaction" approach, which is available only in rare and extraordinary circumstances (see Burnet v. Logan, 283 U.S. 404 (1931)), the Seller does not include the contingent consideration in the aggregate purchase price at the time of closing but instead reports gain on each contingent payment as it is received. The IRS has consistently taken the position that open transaction treatment is disfavored and should be available only where the fair market value of the contingent right is "not susceptible of being ascertained" with reasonable accuracy.
Preliminary Position. For purposes of this preliminary allocation, we recommend treating the full $14,000,000 maximum earnout as part of the aggregate purchase price at closing. This "closed transaction" approach is supported by several factors: (i) the earnout has a readily determinable maximum amount ($14,000,000); (ii) the earnout milestones are specific and binary (FDA clearance/approval and CMS coding/reimbursement), making it possible to assess the probability of achievement; (iii) the clinical and regulatory progress of the OncuPath-HER3™ assay suggests a reasonable probability that both milestones will be achieved within the Earnout Period; and (iv) the closed transaction approach provides certainty and simplicity for purposes of the initial allocation and Form 8594 filing.
Under this approach, the $14,000,000 earnout is allocated to the asset class or classes most closely associated with the milestone-generating asset — specifically, the OncuPath-HER3™ PMA supplement and related intellectual property, which fall within Class V (intangible assets). If the earnout payments are ultimately less than $14,000,000 (e.g., if one or both milestones are not achieved), an adjustment to the allocation would be made, and a supplemental Form 8594 would be filed to reflect the revised consideration.
Alternative Approach. An alternative approach was discussed with the client and Haverford & Lane LLP: treating the earnout as contingent consideration eligible for installment sale reporting under IRC § 453. Under this approach, GDT could potentially defer recognition of the portion of gain attributable to the earnout until the milestone payments are actually received. However, IRC § 453(f)(6)(C) and the composition of the Purchased Assets (which include significant depreciable personal property subject to IRC § 1245 recapture and IRC § 197 intangibles subject to recapture under § 197(f)(7)) may limit the availability or benefit of installment sale treatment. In particular, depreciation recapture income must be recognized in the year of sale regardless of whether installment reporting is otherwise elected. A more detailed analysis of the installment sale considerations is set forth in the separate Tax Structuring Memorandum prepared by this office; the conclusions of that analysis are summarized in Section VI.D below.
B. Impact on Seller's Gain Recognition
The treatment of the earnout consideration has direct implications for the timing, amount, and character of GDT's recognized gain from the sale of the OncuPath Business.
If the earnout is treated as part of the aggregate purchase price at closing (the recommended approach), GDT recognizes its full gain in the taxable year of the closing (2023), calculated as the difference between the $140,000,000 total consideration and GDT's adjusted tax basis in the Purchased Assets, as allocated across the seven asset classes. If either or both earnout milestones are not achieved, GDT would recognize a loss (or reduce its previously recognized gain) in the taxable year in which the contingency lapses.
If installment sale treatment is available and elected for the earnout component, GDT would defer a portion of its gain to the taxable year or years in which the earnout payments are received (i.e., the year of Milestone 1 achievement, if any, and the year of Milestone 2 achievement, if any). However, as noted above, depreciation recapture income under IRC § 1245 and amortization recapture under IRC § 197(f)(7) must be recognized in full in the year of sale regardless of the installment election.
The allocation of earnout consideration to specific asset classes also affects the character of the gain recognized by GDT. To the extent the earnout is allocated to Class V intangible assets (such as the OncuPath-HER3™ intellectual property), the gain on that portion of the earnout is subject to ordinary income treatment to the extent of prior § 197 amortization recapture, with any excess treated as § 1231 gain (potentially long-term capital gain). To the extent the earnout is allocated to Class VII goodwill, the gain is treated as long-term capital gain (assuming GDT's basis in self-created goodwill is zero or nominal), which is the most favorable character from GDT's perspective.
V. Preliminary Purchase Price Allocation
A. Methodology
The preliminary fair market values assigned to each class of Purchased Assets were estimated based on the following sources and methodologies:
(a) Haverford & Lane LLP's carve-out financial statements and asset appraisals prepared in connection with the OncuPath Business carve-out, including depreciated replacement cost analyses for tangible personal property, relief-from-royalty analyses for intellectual property and trademarks, and multi-period excess earnings analyses for customer relationships;
(b) Management representations and supporting data provided by Martin Kowalski, Chief Financial Officer of GDT, and other members of GDT management, including historical revenue data, customer retention metrics, and projected cash flows for the OncuPath Business;
(c) Comparable transaction data and market intelligence provided by Brindoval Partners LLC (Victor Sandoval, Managing Director; Elaine Cho, Vice President), GDT's financial advisor for the transaction; and
(d) Independent assessment and review by the Calderwood & Harkness tax team, informed by our experience with purchase price allocations in comparable diagnostics and life sciences transactions.
The residual method was applied as follows: the total consideration of $140,000,000 was first allocated to Classes I through III (where no amounts were allocable in this transaction), then to Class IV (tangible personal property) based on fair market value, then to Class V (intangible assets) based on fair market value, then to Class VI (trademarks and trade names) based on fair market value, and finally, any remaining unallocated consideration was assigned to Class VII (goodwill and going-concern value) as the residual. The resulting allocation is presented in Section V.B below.
It bears emphasis that these are preliminary fair market value estimates. The final allocation will be refined based on: (i) the completion of independent appraisals by Haverford & Lane LLP; (ii) the finalization of the post-closing NWC true-up; and (iii) the outcome of negotiations with Meridian and its counsel. The estimates presented herein are intended to provide a reasonable starting framework for those negotiations.
B. Allocation Table
The preliminary purchase price allocation is summarized in the following table:
The residual calculation confirms the Class VII allocation: $140,000,000 minus ($18,200,000 + $83,800,000 + $9,400,000) equals $28,600,000.
Each asset class is discussed in detail in Sections V.C through V.F below.
C. Class IV — Tangible Personal Property: $18,200,000
The $18,200,000 allocated to Class IV encompasses all tangible personal property included in the Purchased Assets, specifically:
Laboratory and Diagnostic Equipment. Laboratory instruments, diagnostic analyzers, automated sample processing systems, imaging and quantification platforms, and related hardware located at the OncuPath reference laboratory at 4820 Towne Centre Drive, Suite 200, San Diego, California 92121. This equipment is essential to the performance of OncuPath diagnostic assays and includes proprietary and third-party instruments configured for OncuPath-specific workflows.
Manufacturing and Kitting Equipment. Manufacturing equipment, kitting machinery, quality control instrumentation, and packaging systems located at the Carlsbad manufacturing facility at 925 Industrial Court, Carlsbad, California 92010. This equipment is used in the production and assembly of OncuPath assay kits for distribution to customer laboratories.
Inventory. Reagent inventory (including proprietary probe reagents, signal amplification chemicals, and assay buffers), consumable supplies (slides, coverslips, pipette tips, and related laboratory consumables), work-in-progress inventory, and finished goods inventory of OncuPath assay kits ready for shipment.
Furniture, Fixtures, and Other Tangible Property. Office furniture, laboratory fixtures, computer hardware, and other tangible personal property exclusively used in the OncuPath Business at both facilities.
The fair market values of the Class IV assets were estimated by Haverford & Lane LLP using a depreciated replacement cost methodology, which considers the current cost of replacing each asset with a functionally equivalent new asset, adjusted for physical deterioration, functional obsolescence, and economic obsolescence. This methodology is consistent with standard appraisal practices for used laboratory and manufacturing equipment in the diagnostics industry.
From Seller's perspective, the gain allocated to Class IV assets is subject to IRC § 1245 depreciation recapture to the extent of GDT's prior depreciation deductions on these assets, with any excess gain treated as IRC § 1231 gain (potentially long-term capital gain, subject to the § 1231 netting rules). GDT's adjusted tax bases in the Class IV assets are being confirmed by Haverford & Lane LLP based on GDT's depreciation schedules and fixed asset register.
From Buyer's perspective, the $18,200,000 allocated to Class IV provides Meridian with depreciable basis in tangible personal property recoverable under the Modified Accelerated Cost Recovery System ("MACRS") over five-year or seven-year recovery periods, depending on the specific asset type and applicable asset class under Revenue Procedure 87-56 (as modified). Meridian may also be eligible for bonus depreciation under IRC § 168(k) with respect to a portion of these assets, subject to the phase-down schedule applicable to property placed in service after December 31, 2022.
D. Class V — Intangible Assets: $83,800,000
The $83,800,000 allocated to Class V is the largest component of the purchase price allocation and encompasses all intangible assets included in the Purchased Assets other than trademarks and trade names (which are allocated to Class VI) and goodwill and going-concern value (which are allocated to Class VII). The Class V allocation is broken down into three subcategories as follows:
1. Intellectual Property (Patents, Trade Secrets, Know-How, and Vantage License): $52,600,000
The intellectual property component of the Class V allocation, valued at $52,600,000, represents the single largest asset or asset group in the entire purchase price allocation. This subcategory includes the following:
Issued Patents. Fourteen (14) issued United States patents covering various aspects of the OncuPath diagnostic assay technology, including probe design and synthesis, signal amplification chemistry, assay workflow protocols, image analysis algorithms, bioinformatics scoring methods, and quality control procedures. The issued patents have remaining terms ranging from approximately seven to seventeen years and provide Meridian with exclusivity over core elements of the OncuPath technology platform.
Pending Patent Applications. Seven (7) pending United States patent applications covering next-generation extensions of the OncuPath technology, including the OncuPath-HER3™ assay design and certain improvements to the bioinformatics scoring algorithms. If issued, these patents would further strengthen Meridian's competitive position in the companion diagnostics market.
Trade Secrets and Proprietary Know-How. Extensive proprietary knowledge related to assay development, manufacturing processes, quality control protocols, reagent formulation, probe design, and customer-specific customization workflows. This know-how has been developed by GDT over approximately nine years of operations and is not publicly available or disclosed in the issued patents.
Vantage Molecular Sciences License. The exclusive license from Vantage Molecular Sciences, Inc. for probe-labeling technology pursuant to the license agreement dated September 12, 2019 (the "Vantage License"). The Vantage License grants the licensee exclusive rights to use specified probe-labeling technology in the field of companion diagnostics for solid tumors, with a term extending through September 12, 2034 (fifteen years from execution), subject to renewal. Consent to the assignment of the Vantage License to Meridian was obtained from Vantage Molecular Sciences, Inc. on July 14, 2023. The Vantage License is a critical input to the OncuPath assay manufacturing process, and the probe-labeling technology covered by the license is not readily available from alternative sources.
The intellectual property was valued primarily using a combination of the relief-from-royalty method and the income approach. Under the relief-from-royalty method, the value of the intellectual property is estimated based on the present value of the hypothetical royalty payments that Meridian would be required to make to license the technology from a third party, applied to projected OncuPath revenues over the remaining useful life of the intellectual property. The royalty rate was benchmarked against comparable license transactions in the molecular diagnostics industry and adjusted for the breadth and strength of the OncuPath patent portfolio. Under the income approach, the value was cross-checked by reference to the projected future cash flows attributable to the intellectual property, discounted at a risk-adjusted rate of return appropriate for early-to-mid-stage companion diagnostics technology.
Key inputs to the valuation included OncuPath Business revenues of $47,600,000 for fiscal year 2022, management's revenue projections for fiscal years 2023 through 2030, customer attrition assumptions, competitive dynamics in the companion diagnostics market, and the probability-weighted outcomes for the pending OncuPath-HER3™ PMA supplement.
All intellectual property assets in this subcategory are amortizable by Buyer over fifteen (15) years under IRC § 197, as they constitute "section 197 intangibles" within the meaning of IRC § 197(d)(1)(C) (patents, copyrights, formulas, processes, and similar items) and IRC § 197(d)(1)(D) (customer-based intangibles). The anti-churning rules of IRC § 197(f)(9) do not apply because Buyer and Seller are unrelated parties within the meaning of IRC § 197(f)(9)(C).
From Seller's perspective, gain on the disposition of § 197 intangibles is subject to recapture under IRC § 197(f)(7), which recharacterizes as ordinary income the portion of gain attributable to prior § 197 amortization deductions claimed by GDT. Any gain in excess of the recaptured amortization is treated as IRC § 1231 gain.
2. Customer Relationships and Contracts: $27,800,000
The customer relationships and contracts component of the Class V allocation, valued at $27,800,000, reflects the value of the OncuPath Business's established customer base and the associated contracted revenue streams. The Purchased Assets include all customer contracts transferred pursuant to the Assignment and Assumption Agreement, encompassing relationships with hospitals, academic medical centers, reference laboratories, and pharmaceutical company partners that utilize OncuPath assays in clinical trials and commercial companion diagnostic programs.
The customer relationships were valued using the multi-period excess earnings method ("MPEEM"), which isolates the expected future cash flows attributable to existing customer relationships (as distinct from cash flows attributable to other assets, such as intellectual property, trademarks, and tangible property) and discounts those cash flows to present value at an appropriate rate of return. Key assumptions in the MPEEM analysis included:
(a) An expected customer retention rate of approximately 92% per annum, based on GDT's historical customer attrition data for the OncuPath Business;
(b) A revenue attrition curve reflecting the gradual loss of customers over the projection period, partially offset by volume growth from retained customers;
(c) Contributory asset charges for the use of intellectual property, trademarks, tangible assets, and assembled workforce in generating customer-related cash flows; and
(d) A discount rate reflecting the risk profile of the customer relationship intangible, which is generally higher than the weighted average cost of capital for the OncuPath Business as a whole due to the uncertainty inherent in customer retention.
Customer relationships are amortizable by Buyer over fifteen (15) years under IRC § 197 as customer-based intangibles within the meaning of IRC § 197(d)(2). From Seller's perspective, gain on the customer relationship intangible is subject to the same recapture and character rules described above for intellectual property.
3. Real Property Interests (Leasehold Improvements and Interests): $3,400,000
The real property interests component of the Class V allocation, valued at $3,400,000, includes the following:
Below-Market Lease Value — 4820 Towne Centre Drive. The assigned leasehold interest at 4820 Towne Centre Drive, Suite 200, San Diego, California 92121 (the primary OncuPath reference laboratory and R&D facility) carries contractual lease terms that are below current market rates for comparable laboratory space in the Torrey Pines / University City submarket of San Diego. The difference between the contractual rent and the estimated market rent, discounted over the remaining lease term, generates a favorable lease intangible with an estimated fair market value that is included in this subcategory.
Sublease Value — 925 Industrial Court. The sublease at 925 Industrial Court, Carlsbad, California 92010 (the OncuPath manufacturing and kitting facility) expires on December 31, 2025. The sublease terms are modestly below market, contributing a smaller favorable lease intangible. The relatively short remaining term limits the value attributable to this interest.
Leasehold Improvements. Leasehold improvements at both the San Diego and Carlsbad facilities, including laboratory build-outs, clean room infrastructure, HVAC modifications, electrical upgrades, and security systems specifically installed for the OncuPath Business operations.
These real property interests are amortizable by Buyer over the remaining lease terms or over fifteen years under IRC § 197, whichever period is applicable. In the case of leasehold improvements, amortization is generally over the remaining term of the lease (including renewal periods reasonably expected to be exercised) or, if the leasehold interest qualifies as a section 197 intangible, over the fifteen-year § 197 period.
E. Class VI — Trademarks and Trade Names: $9,400,000
The $9,400,000 allocated to Class VI encompasses the three registered trademarks in the OncuPath brand family:
(i) OncuPath™ — United States Patent and Trademark Office Registration No. 5,847,321;
(ii) OncuPath-HER3™ — United States Patent and Trademark Office Registration No. 6,412,088; and
(iii) OncuPath-GENOMARK™ — United States Patent and Trademark Office Registration No. 6,118,754.
The trademarks are classified as Class VI assets — IRC § 197 intangibles other than goodwill and going-concern value — because they constitute "trademarks and trade names" within the meaning of IRC § 197(d)(1)(F). Class VI occupies a distinct position in the residual method hierarchy: consideration is allocated to Class VI only after Classes I through V have been fully allocated, but before the residual amount is assigned to Class VII goodwill.
The trademarks were valued using the relief-from-royalty method, applying a market-derived royalty rate to projected OncuPath brand-attributed revenues over the estimated remaining useful life of the trademarks. The royalty rate was benchmarked against comparable trademark license transactions in the in vitro diagnostics and life sciences industries, taking into account the strength and recognition of the OncuPath brand within the companion diagnostics market, the breadth of the trademark registrations, and the projected revenue trajectory of the OncuPath Business.
The trademarks are amortizable by Buyer over fifteen (15) years under IRC § 197. The distinction between self-created and acquired intangibles (which is relevant for certain § 197 planning considerations) is not at issue here, as the trademarks are acquired intangibles in Meridian's hands.
From Seller's perspective, the treatment of gain on the trademark assets is similar to that for other § 197 intangibles: gain is subject to recapture of prior § 197 amortization deductions as ordinary income under IRC § 197(f)(7), with any excess treated as § 1231 gain.
F. Class VII — Goodwill and Going-Concern Value (Residual): $28,600,000
Under the residual method, the amount allocated to Class VII is determined by subtracting the aggregate fair market values allocated to all other classes from the total consideration:
$140,000,000 − ($0 + $0 + $0 + $18,200,000 + $83,800,000 + $9,400,000) = $28,600,000
The $28,600,000 residual allocation to Class VII represents the goodwill and going-concern value of the OncuPath Business — that is, the intangible value attributable to the OncuPath Business as a going concern that is not separately identifiable or allocable to any specific asset in Classes I through VI. This residual value reflects, among other things:
Going-Concern Value. The incremental value of the OncuPath Business as an assembled, functioning enterprise over and above the sum of its individual assets. This value arises from the synergies, operational efficiencies, and competitive advantages that result from having all of the OncuPath Business assets organized and operating together as a cohesive business unit.
Assembled Workforce. At the Closing, eighty-three (83) employees of GDT who were primarily engaged in the OncuPath Business were offered positions with Meridian, and seventy-eight (78) of those employees accepted and transferred to Meridian at or shortly after the Closing. Key personnel who transferred include Dr. Lara Okonkwo (Vice President, Assay Development), Samuel Briggs (Director, Manufacturing Operations), and Yuki Tanabe (Senior Director, Commercial Operations). While the value of an assembled workforce cannot be separately amortized under IRC § 197(d)(1)(A) (which specifically includes "workforce in place" as a § 197 intangible), the assembled workforce value is subsumed within the Class VII goodwill allocation for purposes of the purchase price allocation.
Other Non-Separately Identifiable Intangible Value. Any additional intangible value not captured in the individual asset valuations in Classes IV through VI, including the OncuPath Business's reputation in the companion diagnostics market, its established relationships with key opinion leaders and thought leaders in oncology, and its pipeline of potential new assay applications beyond those specifically valued in Class V.
The Class VII goodwill is amortizable by Buyer over fifteen (15) years under IRC § 197. From Seller's perspective, gain on the goodwill component is treated as long-term capital gain, assuming that GDT's adjusted tax basis in self-created goodwill is zero or nominal (which is the typical result for internally generated goodwill). This is the most favorable character treatment from Seller's perspective, as long-term capital gain is taxed at more favorable rates than ordinary income at the shareholder level (particularly for Pinnacle's individual limited partners).
VI. Tax Implications for Seller (GDT)
A. Character of Gain by Asset Class
The character of GDT's recognized gain from the sale of the Purchased Assets varies by asset class, depending on the nature of the assets and the applicable recapture provisions:
Class IV — Tangible Personal Property ($18,200,000). Gain recognized on the disposition of Class IV assets is subject to IRC § 1245 depreciation recapture to the extent of GDT's aggregate prior depreciation deductions on those assets. Under § 1245(a)(1), the "recomputed basis" of the property is compared to the amount realized, and any gain is treated as ordinary income to the extent of the lesser of (i) the recognized gain or (ii) the aggregate depreciation deductions previously allowed or allowable with respect to the property. Any gain in excess of the recaptured depreciation is treated as IRC § 1231 gain, which is subject to the § 1231 netting rules: if the taxpayer's aggregate § 1231 gains exceed its aggregate § 1231 losses for the taxable year, the net gain is treated as long-term capital gain; if aggregate losses exceed gains, the net loss is treated as ordinary loss. GDT's historical depreciation schedules are being reviewed by Haverford & Lane LLP to determine the extent of § 1245 recapture exposure.
Class V — Intangible Assets ($83,800,000). Gain recognized on the disposition of § 197 intangible assets is subject to recapture under IRC § 197(f)(7). This provision requires that gain on the disposition of a § 197 intangible be treated as ordinary income to the extent of prior § 197 amortization deductions taken by the taxpayer with respect to any § 197 intangible held in the same transaction or series of related transactions. Importantly, the § 197(f)(7) recapture rule is applied on an aggregate basis — that is, the total gain is recharacterized as ordinary income to the extent of the aggregate amortization deductions previously claimed on all § 197 intangibles disposed of as part of the same transaction. This aggregate approach may result in a larger ordinary income recapture amount than would result if recapture were determined on an asset-by-asset basis. Any gain in excess of the recaptured amortization is treated as § 1231 gain.
Class VI — Trademarks and Trade Names ($9,400,000). The treatment of gain on trademarks and trade names is similar to that for other § 197 intangibles in Class V. Gain is subject to recapture of prior § 197 amortization deductions as ordinary income, with any excess treated as § 1231 gain.
Class VII — Goodwill and Going-Concern Value ($28,600,000). Gain recognized on the disposition of goodwill is treated as long-term capital gain, assuming GDT's adjusted tax basis in self-created goodwill is zero or nominal (which is the expected result, as internally generated goodwill is not amortizable for tax purposes and GDT has not previously taken any amortization deductions with respect to its self-created goodwill). This is the most favorable character treatment from Seller's perspective.
Overall Observation. The foregoing analysis reveals a fundamental tension that will inform the purchase price allocation negotiations: maximizing the allocation to Class VII goodwill is favorable to Seller because it produces long-term capital gain, while maximizing allocations to Classes IV, V, and VI is favorable to Buyer because it provides depreciable and amortizable basis that generates current tax deductions. This tension is inherent in virtually every asset acquisition under IRC § 1060 and will be a central focus of the negotiation with Meridian's counsel.
B. Corporate-Level Tax
GDT is a C corporation organized under the laws of the State of Delaware. Gain recognized by GDT on the sale of the Purchased Assets is subject to federal corporate income tax at the applicable rate of 21% under IRC § 11(b). GDT will also be subject to applicable state income and franchise taxes, as discussed in Section VI.C below.
Because GDT is a C corporation, the gain from the asset sale is recognized and taxed at the corporate level before any distributions can be made to GDT's shareholders, including Pinnacle Biosciences Partners Fund III, L.P. (the 68.4% majority shareholder). Distributions from GDT to its shareholders will generally be treated as dividends to the extent of GDT's earnings and profits (including the earnings and profits generated by the gain on the asset sale), and will be taxed again at the shareholder level — resulting in the well-known "double taxation" characteristic of C corporation structures.
For Pinnacle, which is a limited partnership, the character of income received from GDT (whether dividend income or, in the event of a liquidating distribution, capital gain) will flow through to Pinnacle's limited partners on their respective Schedules K-1. The tax treatment at the limited partner level will depend on the character of the income, the individual partner's tax situation, and any applicable provisions of the Pinnacle Fund III partnership agreement regarding the allocation of income, gain, loss, and deduction among the partners.
C. California Apportionment
GDT is headquartered in San Diego, California, and all operations of the OncuPath Business are conducted from facilities located in California (the San Diego laboratory and R&D facility and the Carlsbad manufacturing facility). Accordingly, GDT's gain from the sale of the OncuPath Business assets is subject to the California franchise tax.
California apportions the income of multistate businesses using a single-sales-factor formula under Revenue and Taxation Code § 25128.7, which applies to tax years beginning on or after January 1, 2013. Under the single-sales-factor formula, the portion of a taxpayer's business income apportioned to California is determined by the ratio of the taxpayer's California sales to its total sales everywhere.
With respect to gain from the sale of intangible assets, California's market-based sourcing rules (Revenue and Taxation Code § 25136) generally source sales of intangibles to the location of the customers or users of the intangible property. This raises complex questions regarding the apportionment of GDT's gain from the sale of the OncuPath intellectual property, customer relationships, and goodwill, as the OncuPath Business's customers are located in multiple states. To the extent that the gain is sourced to California under the market-based sourcing rules, it would be included in GDT's California-apportioned income and subject to California franchise tax at the applicable rate (currently 8.84% for C corporations).
A detailed analysis of the California apportionment and sourcing of the gain from the OncuPath asset sale is being prepared in coordination with Haverford & Lane LLP and will be provided in a separate California state tax memorandum. The estimated California franchise tax impact will be quantified upon completion of that analysis.
D. Installment Sale Considerations for Earnout
As noted in Section IV above, an alternative to the closed-transaction approach for the $14,000,000 earnout is to treat the earnout as contingent consideration eligible for installment sale reporting under IRC § 453. The following is a summary of the key considerations; a more detailed analysis is set forth in the separate Tax Structuring Memorandum prepared by this office.
If installment sale treatment under IRC § 453 is elected for the earnout component, GDT would report the portion of gain attributable to the earnout payments as and when such payments are received — specifically, the gain associated with Milestone 1 ($8,000,000) would be recognized in the taxable year in which FDA clearance or approval of OncuPath-HER3™ is obtained (expected by August 8, 2025), and the gain associated with Milestone 2 ($6,000,000) would be recognized in the taxable year in which CMS issues a unique HCPCS code and first Medicare reimbursement is received (expected by August 8, 2026).
However, several limitations on installment sale treatment must be considered:
(a) Dealer Dispositions. IRC § 453(b)(2) excludes "dealer dispositions" from eligibility for installment sale treatment. GDT's sale of the OncuPath Business is not a dealer disposition, so this exclusion is not applicable.
(b) Depreciation Recapture. Under IRC §§ 1245(a) and 1250(a), depreciation recapture income must be recognized in full in the year of sale, regardless of whether the taxpayer otherwise elects installment sale treatment. This means that GDT's § 1245 recapture on Class IV tangible personal property and its § 197(f)(7) recapture on Class V and Class VI intangibles must be recognized in 2023 in all events. The effect is to "accelerate" a significant portion of the ordinary income component of GDT's gain into the year of closing, reducing the benefit of deferring the remaining gain through installment reporting.
(c) Interest on Deferred Tax. IRC § 453A(c) requires the payment of interest on the deferred tax liability attributable to non-dealer installment sales where the face amount of the outstanding installment obligations arising during the taxable year exceeds $5,000,000. Because the maximum earnout of $14,000,000 exceeds this threshold, GDT would be required to pay interest on the deferred tax associated with the unrecognized gain attributable to the earnout, effectively offsetting a portion of the deferral benefit.
(d) Practical Consideration. The maximum earnout of $14,000,000 represents only 10% of the total consideration of $140,000,000. The relatively modest magnitude of the earnout, combined with the depreciation recapture acceleration and the interest charge on deferred tax, suggests that the net benefit of installment sale treatment for the earnout component may be limited. The closed-transaction approach, which provides certainty and simplicity, may be the preferred course of action.
The final determination regarding the election of installment sale treatment versus closed-transaction reporting for the earnout will be made in coordination with GDT's tax advisors at Haverford & Lane LLP, taking into account GDT's overall tax planning for the 2023 taxable year and subsequent years.
VII. Tax Implications for Buyer (Meridian)
A. Step-Up in Basis
One of the primary tax advantages of the asset purchase structure for Meridian is the full step-up in tax basis for all Purchased Assets to their allocated fair market values. Unlike a stock acquisition (in which the acquired corporation's historical tax bases in its assets generally carry over to the new owner), an asset acquisition under IRC § 1012 provides the buyer with a cost basis in each acquired asset equal to the portion of the total consideration allocated to that asset. This basis step-up generates future depreciation and amortization deductions that reduce Meridian's taxable income over the applicable recovery periods, providing a significant present-value tax benefit.
The total stepped-up basis available to Meridian across all asset classes is $140,000,000, allocated as set forth in Section V.B. The annual depreciation and amortization deductions flowing from this stepped-up basis are summarized in Section VII.B below.
B. Depreciation and Amortization Schedule (Summary)
The following summarizes the depreciation and amortization treatment for each asset class from Meridian's perspective:
Class IV — Tangible Personal Property ($18,200,000). Depreciable under the Modified Accelerated Cost Recovery System ("MACRS") over recovery periods of five (5) or seven (7) years, depending on the specific asset type and the applicable asset class under Revenue Procedure 87-56, as modified. Laboratory instruments and diagnostic analyzers are generally classified as five-year property (Asset Class 57.0 — Distributive Trades and Services), while manufacturing equipment may be classified as seven-year property depending on its specific use. Meridian may also be eligible for bonus depreciation under IRC § 168(k) for qualified property placed in service during the taxable year of acquisition. Under the current phase-down schedule, the bonus depreciation percentage for pr